Search | Clinical Trials Finder

Conditions: Attention Deficit Hyperactivity Disorder, Delayed Sleep Phase Type Circadian Rhythm Sleep Disorder
Interventions: Polarized glasses designed to filter out blue light; Device
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Cocaine-Related Disorders
Interventions: Bupropion; Drug
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1995 – 1998
U.S. locations: 1
States / cities: New York, New York

Conditions: Oppositional-Defiant Disorder
Interventions: Parent management training (PMT), Collaborative problem solving (CPS), Waitlist control; Behavioral
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 8 Years to 14 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: ADHD
Interventions: Mixed amphetamine salts (ADDERALL XR), Atomoxetine hydrochloride; Drug
Lead sponsor: Shire; Industry
Eligibility: 6 Years to 12 Years
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autism, Attention Deficit Hyperactivity Disorder
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 6 Years to 11 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: ADHD
Interventions: Medication as usual, STAR; Other
Lead sponsor: Florida International University; Other
Eligibility: 12 Years to 16 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Aripiprazole; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 8 Years to 12 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Posttraumatic Stress Disorder With Attention Defic
Interventions: Atomoxetine, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: ADHD
Interventions: Central Executive Training: Working Memory, Central Executive Training: Inhibitory Control; Behavioral
Lead sponsor: Florida State University; Other
Eligibility: 8 Years to 12 Years
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: ADHD
Interventions: Methylphenidate Transdermal System; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 32
States / cities: Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more

Conditions: Oppositional Defiant Disorder
Interventions: Parent Training plus Emotion Coaching, Parent Training only; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 3 Years to 7 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: OPDC-34712, Placebo, Stimulant Therapy; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 740 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 35
States / cities: Little Rock, Arkansas • Beverly Hills, California • Irvine, California + 32 more

Conditions: Attention Deficit Disorder With Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Interventions: Incredible Years Program; Behavioral
Lead sponsor: Tufts Medical Center; Other
Eligibility: 22 Months to 38 Months
Enrollment: 345 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 9
States / cities: Chelsea, Massachusetts • Dorchester, Massachusetts • Jamaica Plain, Massachusetts + 6 more

Conditions: Attention Deficit Hyperactivity Disorder Symptoms
Interventions: Behavioral/organizational skills intervention augmented with digital health application; Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 11 Years to 15 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate 0.15 mg/kg, Low-Intensity BMOD, Methylphenidate 0.3 mg/kg, Placebo, Methylphenidate 0.6 mg/kg, High Intensity BMOD; Drug · Behavioral
Lead sponsor: Florida International University; Other
Eligibility: 5 Years to 12 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 2
States / cities: Miami, Florida • Buffalo, New York

Conditions: Cerebrovascular Accident, Transient Ischemic Attack, ADHD
Interventions: atomoxetine, Stimulants, No intervention (general population); Drug · Other
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 72,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: Methylphenidate HCl, Risperidone, Parent Management Training (PMT), Placebo; Drug · Behavioral
Lead sponsor: Michael Aman; Other
Eligibility: 6 Years to 12 Years
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 4
States / cities: Stony Brook, New York • Cleveland, Ohio • Columbus, Ohio + 1 more

Conditions: ADHD, Attention Deficit Hyperactivity Disorder
Interventions: Naltrexone, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Attention Deficit Disorder With Hyperactivity
Interventions: NFC-1 100 mg, NFC-1 200 mg, NFC-1 400 mg, NFC-1 800 mg; Drug
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 3
States / cities: Maitland, Florida • Miami, Florida • Las Vegas, Nevada

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: parent training; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 6 Years to 14 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Attention Deficit/Hyperactivity Disorder, Emotional Dysfunction, Irritable Mood
Interventions: Multinutrients; a 36-ingredient blend of vitamins, minerals, amino acids, and antioxidants; Dietary Supplement
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 6 Years to 17 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Atomoxetine 80 mg/d, Placebo, OROS methylphenidate HCl 54 mg/d, JNJ-31001074 3 mg/d, JNJ-31001074 1 mg/d, JNJ-31001074 10 mg/d; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 430 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Little Rock, Arkansas • Lafayette, California • Los Alamitos, California + 32 more

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: CLONICEL (Clonidine HCl sustained release); Drug
Lead sponsor: Shionogi; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 27
States / cities: Little Rock, Arkansas • El Centro, California • Irvine, California + 23 more

Conditions: ADHD, Weight Loss
Interventions: Adaptive Working Memory Training, Non-adaptive cognitive training; Behavioral
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Burlington, Vermont

Search by objective public record fields.

Blue Wavelength Light-blocking Glasses in ADHD-Insomnia

Cocaine Abuse and Attention Deficit Disorder - 3

Comparison of Two Psychosocial Therapies for Treating Children With Oppositional-Defiant Disorder

Analog Classroom Study Comparison of ADDERALL XR With STRATTERA in Children Aged 6-12 With ADHD

A Pilot Study of Daytrana TM in Children With Autism Co-Morbid for Attention Deficit Hyperactivity Disorder (ADHD) Symptoms

Improving Medication Adherence in ADHD Adolescents

Study of Aripiprazole (Abilify) in Children With ADHD (Attention Deficit Hyperactivity Disorder)

Atomoxetine and Executive Function in PTSD

Central Executive Training (CET) for ADHD

Evaluate the Safety and Efficacy of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Parent Training and Emotion Coaching for Children With Limited Prosocial Emotions

Study of the Safety and Efficacy of OPC-34712 as a Complementary Therapy in the Treatment of Adult Attention Deficit/Hyperactivity Disorder

Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders

Development of a Mobile App for an Executive Functioning Intervention for Adolescents

Behavioral Treatment, Drug Treatment, and Combined Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

Safety Study of Atomoxetine and Cerebrovascular Outcomes

Treatment of Severe Childhood Aggression (The TOSCA Study)

A Double-Blind Comparison of Naltrexone and Placebo in Adults With Attention Deficit Hyperactivity Disorder

Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD

Effectiveness Study of Videoconferencing on Teaching Parent Training Skills to Parents of Children With Attention Deficit Hyperactivity Disorder (ADHD)

Optimizing Research With Diverse Families - Feasibility and Acceptability Study (FAST)

A Study to Evaluate 3 Different Doses of JNJ-31001074 in the Treatment of Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Open-Label, Chronic Exposure, Safety Study of CLONICEL (Clonidine HCl Sustained Release) in Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)

Obesity Treatment Enhanced With Working Memory Training